Spero Expands Leadership Team, Advisory Board With Industry Veterans

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced the appointment of John Tomayko, M.D., as Chief Medical Officer. Dr. Tomayko, who is board certified in internal medicine and infectious disease, brings more than 20 years of experience in the development of innovative antibacterial compounds to the pioneering efforts at Spero, in addition to expertise in the rational design of clinical development pathways. Other recent additions to the Spero team include, Scott Coleman, Ph.D., as Head of Nonclinical Development and Tim Keutzer as Vice President of Development. Milind S. Deshpande, Ph.D., President and Chief Executive Officer of Achillion, who has served on the Spero Board of Directors since inception, has been elevated to the position of Chairman of the Board. He succeeds Jean Francois Formela of Atlas Venture, Spero's founding investor, as Chair.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.